Login / Signup

Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy.

Stanley L CohanKeith EdwardsLindsay LucasTiffany Gervasi-FollmarJudy O'ConnorJessica SiutaVineetha KamathLore GartenChiayi ChenJames ThomasKyle SmootKiren Kresa-ReahlKateri J Spinelli
Published in: Multiple sclerosis journal - experimental, translational and clinical (2019)
Teriflunomide therapy initiated without natalizumab washout resulted in a low rate of return of disease activity. Clinicians may consider this a worthwhile strategy when transitioning clinically stable patients off natalizumab to another therapy.ClinicalTrials.gov Identifier: NCT01970410.
Keyphrases